The DOI matches its Crossref record.
Coronary artery stents: a rapid systematic review and economic evaluation
Open accessAbstract
OBJECTIVES: To assess the effectiveness and cost-effectiveness of the use of coronary artery stents in patients with coronary heart disease (CHD). DATA SOURCES: Electronic databases. REVIEW METHODS: The review was conducted following accepted guidelines for conducting systematic reviews. Randomised controlled trials that include comparisons of percutaneous transluminal coronary angioplasty (PTCA) versus PTCA with stent, stent versus coronary artery bypass graft (CABG), and drug-eluting stents (DES) versus non-DES in patients with CAD in native or graft vessels and those with stable angina or acute coronary syndrome (ACS) and unstable angina were also included. Data on the following outcome measures were included in the review: combined event rate or event-free survival, death, acute myocardial infarction, target vessel revascularisation, repeat treatment (PTCA, stent or CABG) and binary restenosis. An economic model was developed based on extrapolation of trends in mortality and revascularisation from clinical trials data to a 5-year time horizon. RESULTS: The inclusion criteria were fulfilled by 50 studies comparing the use of stents with PTCA, six comparing stents with CABG and 12 comparing DES eluting stents with non-DES. No studies were identified that compared DES with PTCA or DES with CABG. Existing quality of life data suggest that revascularisation procedures reduce the patient's quality of life for a short period only. Stents were found to be more effective than PTCA in preventing adverse events and revascularisations. In multiple-vessel disease there was no evidence of a difference in mortality (at 1 year) between patients treated surgically and those receiving a stent. Patients treated surgically required fewer revascularisations. There is no evidence of a difference in mortality between patients receiving DES and those treated with bare metal stents at 1 year. A reduction in event rate at 9 and 12 months was found in patients treated with DES. This event rate is primarily made up of increased revascularisation rates in patients treated with bare metal stents. Two-year outcome data from one study indicate that this benefit of DES continues over the longer term. The economic model proved sufficient to indicate long-term trends in cost-effectiveness. CABG was found initially to be more expensive than bare metal stenting in multivessel disease and may have higher immediate risks, but over time the cost differential is reduced and long-term outcomes favour CABG over stenting. A similar situation was found for DES versus CABG in multiple-vessel disease. However, DES may not generally be considered a cost-effective alternative to bare metal stenting in single-vessel disease by policy makers as substantially higher costs are involved with a very small outcome benefit. CONCLUSIONS: DES might be considered cost-effective if the additional cost (compared with ordinary stents) was substantially reduced, the outcome benefits from the use of DES were much improved, and/or its use were targeted on the subgroups of patients with the highest risks of requiring reintervention. Long-term clinical studies are needed that focus on significant outcomes such as mortality. Further research should consider: the differences among plain stents; head-to-head comparisons within DES, CABG compared with DES; and the evaluation of newer non-DES against DES. Evaluation of the effects of revascularisation procedures and especially repeat revascularisation procedures on the patient's quality of life would also be useful, as would the development and testing of risk assessment tools to identify patients likely to need further revascularisations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hobart, J., & Cano, S. (2009) · Health Technology Assessment · doi:10.3310/hta13120 · Cited by 621
Self-monitoring of blood glucose in type 2 diabetes: systematic review
Clar, C., Barnard, K., Cummins, E., Royle, P., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14120 · Cited by 274
RAPID VERSUS FULL SYSTEMATIC REVIEWS: VALIDITY IN CLINICAL PRACTICE?
Watt, A., Cameron, A., Sturm, L., Lathlean, T., Babidge, W., Blamey, S., Facey, K., Hailey, D., Norderhaug, I., & Maddern, G. (2008) · ANZ Journal of Surgery · doi:10.1111/j.1445-2197.2008.04730.x · Cited by 163
Little, P., Turner, S., Rumsby, K., Warner, G., Moore, M., Lowes, J., Smith, H., Hawke, C., Turner, D., Leydon, G., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13190 · Cited by 137
Vitamin K to prevent fractures in older women: systematic review and economic evaluation
Stevenson, M., Lloyd-Jones, M., & Papaioannou, D. (2009) · Health Technology Assessment · doi:10.3310/hta13450 · Cited by 90
Metadata
- Authors
- Hill, R., Bagust, A., Bakhai, A., Dickson, R., Dündar, Y., Haycox, A., Mujica Mota, R., Reaney, A., Roberts, D., Williamson, P., & Walley, T.
- Venue
- Health Technology Assessment
- Published
- 2004-09
- Volume
- 8
- Issue
- 35
- Pages
- iii-iv, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2043258977
- Cited by
- 169
- References
- 0
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coronary artery stents: a rapid systematic review and economic evaluation. https://app.cochat.ai/papers/10.3310/hta8350
- The paper
- Hill, R., Bagust, A., Bakhai, A., Dickson, R., Dündar, Y., Haycox, A., Mujica Mota, R., Reaney, A., Roberts, D., Williamson, P., & Walley, T. (2004). Coronary artery stents: a rapid systematic review and economic evaluation. Health Technology Assessment. https://doi.org/10.3310/hta8350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.